Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 22, Issue 1, Pages 135-150Publisher
IOS PRESS
DOI: 10.3233/JAD-2010-100639
Keywords
Amyloid-beta protein precursor (A beta PP); beta-secretase (BACE1); canine; cholesterol; dog; LRP-1; statin
Categories
Funding
- Alzheimer's Association [IIRG 03-5673]
- Agilent Foundation
Ask authors/readers for more resources
Human studies suggest either a protective role or no benefit of statins against the development of Alzheimer's disease (AD). We tested the hypothesis that statin-mediated cholesterol reduction in aged dogs, which have cognitive impairments and amyloid-beta (A beta) pathology, would improve cognition and reduce neuropathology. In a study of 12 animals, we treated dogs with 80 mg/day of atorvastatin for 14.5 months. We did not observe improvements in discrimination learning; however, there were transient impairments in reversal learning, suggesting frontal dysfunction. Spatial memory function did not change with treatment. Peripheral levels of cholesterol, LDLs, triglycerides, and HDL were significantly reduced in treated dogs. A beta in cerebrospinal fluid and brain remained unaffected. However, beta-secretase-1 (BACE1) protein levels and activity decreased and correlated with reduced brain cholesterol. Finally, lipidomic analysis revealed a significant decrease in the ratio of omega-6 to omega-3 essential fatty in temporal cortex of treated aged dogs. Aged beagles are a unique model that may provide novel insights and translational data that can predict outcomes of statin use in human clinical trials. Treatment with atorvastatin may be beneficial for brain aging by reducing BACE1 protein and omega6:omega3 ratio, however, the potential adverse cognitive outcomes reported here should be more carefully explored given their relevance to human clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available